Aligos Therapeutics Valuation
| ALGS Stock | USD 6.91 0.08 1.14% |
At this time, the firm appears to be undervalued. Aligos Therapeutics shows a prevailing Real Value of $22.22 per share. The current price of the firm is $6.91. Our model approximates the value of Aligos Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.42, shares outstanding of 5.35 M, and Operating Margin of (38.27) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aligos Therapeutics' valuation include:
Price Book 0.5919 | Enterprise Value | Enterprise Value Ebitda 0.5749 | Price Sales 16.07 | Enterprise Value Revenue 0.3833 |
Undervalued
Today
Please note that Aligos Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Aligos Therapeutics is based on 3 months time horizon. Increasing Aligos Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aligos stock is determined by what a typical buyer is willing to pay for full or partial control of Aligos Therapeutics. Since Aligos Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aligos Stock. However, Aligos Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.91 | Real 22.22 | Target 68.2 | Hype 6.97 |
The intrinsic value of Aligos Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aligos Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aligos Therapeutics helps investors to forecast how Aligos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aligos Therapeutics more accurately as focusing exclusively on Aligos Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aligos Therapeutics' intrinsic value based on its ongoing forecasts of Aligos Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aligos Therapeutics' closest peers.
Aligos Therapeutics Cash |
|
Aligos Therapeutics Total Value Analysis
Aligos Therapeutics is presently forecasted to have valuation of (50.51 M) with market capitalization of 42.52 M, debt of 8.38 M, and cash on hands of 159.34 M. The negative valuation of Aligos Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Aligos Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(50.51 M) | 42.52 M | 8.38 M | 159.34 M |
Aligos Therapeutics Investor Information
About 61.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 13.54. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of August 2024. Based on the key indicators related to Aligos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aligos Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Aligos Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aligos Therapeutics has an asset utilization ratio of 5.63 percent. This implies that the Company is making $0.0563 for each dollar of assets. An increasing asset utilization means that Aligos Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aligos Therapeutics Profitability Analysis
Based on Aligos Therapeutics' profitability indicators, Aligos Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Aligos Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-12-31 | Previous Quarter -15.9 M | Current Value -31.5 M | Quarterly Volatility 19.4 M |
For Aligos Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aligos Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aligos Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aligos Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aligos Therapeutics over time as well as its relative position and ranking within its peers.
Aligos Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Aligos Therapeutics is estimated to be -1.896975 with future projections ranging from a low of -2.377875 to a high of -0.6075. Aligos Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -13.54. Please be aware that the consensus of earnings estimates for Aligos Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Aligos Therapeutics Earnings Estimation Breakdown
The calculation of Aligos Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aligos Therapeutics is estimated to be -1.896975 with the future projection ranging from a low of -2.377875 to a high of -0.6075. Please be aware that this consensus of annual earnings estimates for Aligos Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.38 Lowest | Expected EPS | -0.61 Highest |
Aligos Therapeutics Earnings Projection Consensus
Suppose the current estimates of Aligos Therapeutics' value are higher than the current market price of the Aligos Therapeutics stock. In this case, investors may conclude that Aligos Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aligos Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 5 | 8.22% | -3.04 | -1.896975 | -13.54 |
Aligos Therapeutics Ownership Allocation
The market capitalization of Aligos Therapeutics is $42.52 Million. Over half of Aligos Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Aligos Therapeutics Profitability Analysis
The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.8 M).About Aligos Therapeutics Valuation
The stock valuation mechanism determines Aligos Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Aligos Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aligos Therapeutics. We calculate exposure to Aligos Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aligos Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.5 M | 3.7 M | |
| Pretax Profit Margin | (38.15) | (40.06) | |
| Operating Profit Margin | (20.34) | (21.36) | |
| Net Loss | (38.25) | (40.16) |
Aligos Therapeutics Current Valuation Indicators
Aligos Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aligos Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aligos Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aligos Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aligos Therapeutics' worth.Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.